化药新药研发中临床前研究检测

解决方案

标准解读

化学药中主要物质含量分析检测方案(制备液相色谱)

Clandestine laboratories constantly produce new synthetic cannabinoids to circumvent legislative efforts,complicating toxicological analysis. No extensive synthetic cannabinoid quantitative urinary methodsare reported in the literature. We developed and validated a liquid chromatography–tandem mass spec-trometric (LC–MS/MS) method for simultaneously quantifying JWH-018, JWH-019, JWH-073, JWH-081,JWH-122, JWH 200, JWH-210, JWH-250, JWH-398, RCS-4, AM-2201, MAM-2201, UR-144, CP 47,497-C7,CP 47,497-C8 and their metabolites, and JWH-203, AM-694, RCS-8, XLR-11 and HU-210 parent com-pounds in urine. Non-chromatographically resolved alkyl hydroxy metabolite isomers were consideredsemi-quantitative.  Glucuronidase hydrolyzed urine was extracted with 1 ml Biotage SLE+ columns.Specimens were reconstituted in 150 L mobile phase consisting of 50% A (0.01% formic acid in water)and 50% B (0.01% formic acid in 50:50 methanol:acetonitrile). 4 and 25 L injections were performed toacquire data in positive and negative ionization modes, respectively. The LC–MS/MS instrument consistedof a Shimadzu UFLCxr system and an ABSciex 5500 Qtrap massspectrometer with an electrospray source.Gradient chromatographic separation was achieved utilizing a Restek Ultra Biphenyl column with a0.5 ml/min flow rate and an overall run time of 19.5 and 11.4 min for positive and negative mode methods,respectively. Quantification was by multiple reaction monitoring with CP 47,497 compounds and HU-210ionized via negative polarity; all other analytes were acquired in positive mode. Lower and upper limitsof linearity were 0.1–1.0 and 50–100 g/l (r2> 0.994).
检测样品: 化药新药研发
检测项: 临床前研究

上海鑫欣生物科技有限公司

查看联系电话
前往展位

仪器信息网行业应用栏目为您提供29篇化药新药研发检测方案,可分别用于含量测定检测、限度检查检测、注射剂及特殊剂型相关检测、组学研究检测、化合物发现检测、临床前研究检测、分子量检测,参考标准主要有等